

**Saving Hearts and Lives in Advanced Prostate Cancer:
Choosing Between ADT Agonists and Antagonists – Tweetorial #1
References**

Tweet 3

SEER. Cancer stat facts: prostate cancer. National Cancer Institute. Bethesda, MD. Accessed August 12, 2021. <https://seer.cancer.gov/statfacts/html/prost.html>

SEER*Explorer. An interactive website for SEER cancer statistics. Surveillance Research Program, National Cancer Institute. Accessed August 12, 2021. <https://seer.cancer.gov/explorer/>

Tweet 4

Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. *Lancet*. 2012;380(9836):37-43. doi:10.1016/S0140-6736(12)60240-2

Tweet 5

Abidov A, Chehab O. Cardiovascular risk assessment models: Have we found the perfect solution yet? *J Nucl Cardiol*. 2020;27(6):2375-2385. doi:10.1007/s12350-019-01642-x

American College of Cardiology. ASCVD Risk Estimator Plus. Accessed November 1, 2021. <https://tools.acc.org/ascvd-risk-estimator-plus/#!/calculate/estimate>

Centers for Disease Control and Prevention. Heart Disease Facts. Updated September 27, 2021. Accessed November 1, 2021. <https://www.cdc.gov/heartdisease/facts.htm>

Pinthus JH, Shayegan B, Klotz L, et al. The prevalence of cardiovascular disease and its risk factors among prostate cancer patients treated with and without androgen deprivation. *J Clin Oncol*. 2020;38(6_suppl):364-364. doi:10.1200/JCO.2020.38.6_suppl.364

Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. *Circulation*. 2021;143(8):e254-e743. doi:10.1161/CIR.0000000000000950

Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet*. 2004;364(9438):937-52. doi:10.1016/S0140-6736(04)17018-9

Tweet 6

Keane TE. Agonists and antagonists: a review of what is known and recent data on disease-related outcomes from a pooled analysis. Grand Rounds in Urology. September 2015. Accessed November 1, 2021. <https://grandroundsinurology.com/agonists-antagonists/>

Melloni C, Slovin SF, Blemings A, et al. cardiovascular safety of degarelix versus leuprolide for advanced prostate cancer: the PRONOUNCE trial study design. *JACC CardioOncol.* 2020;2(1):70-81. doi:10.1016/j.jaccao.2020.01.004

Roe M. Assessment of cardiovascular risk with the use of androgen deprivation therapy for prostate cancer. *Everyday Urol.* 2017;2(1):16-21.

Shore ND. Current and future management of locally advanced and metastatic prostate cancer. *Rev Urol.* 2020;22(3):110-123.

Tweet 7

Keane TE. Agonists and antagonists: a review of what is known and recent data on disease-related outcomes from a pooled analysis. Grand Rounds in Urology. Accessed November 1, 2021. <https://grandroundsinurology.com/agonists-antagonists/>

Melloni C, Slovin SF, Blemings A, et al. cardiovascular safety of degarelix versus leuprolide for advanced prostate cancer: the PRONOUNCE trial study design. *JACC CardioOncol.* 2020;2(1):70-81. doi:10.1016/j.jaccao.2020.01.004

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (v1.2022). Updated September 10, 2021. Accessed October 1, 2021. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

Roe M. Assessment of cardiovascular risk with the use of androgen deprivation therapy for prostate cancer. *Everyday Urol.* 2017;2(1):16-21.

Shore ND. Current and future management of locally advanced and metastatic prostate cancer. *Rev Urol.* 2020;22(3):110-123.

Tweet 8

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (v1.2022). Updated September 10, 2021. Accessed October 1, 2021. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

Shore ND. Current and future management of locally advanced and metastatic prostate cancer. *Rev Urol.* 2020;22(3):110-123.

Shim M, Bang WJ, Oh CY, Lee YS, Cho JS. Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide. *Investig Clin Urol.* 2019;60(4):244-250. doi:10.4111/icu.2019.60.4.244

Tweet 9

Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. *BJU Int*. 2008;102(11):1531-8. doi:10.1111/j.1464-410X.2008.08183.x

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (v1.2022). Updated September 10, 2021. Accessed October 1, 2021. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

Sari Motlagh R, Abufaraj M, Mori K, et al. the efficacy and safety of relugolix compared with degarelix in advanced prostate cancer patients: a network meta-analysis of randomized trials. *Eur Urol Oncol*. 2021. doi:10.1016/j.euo.2021.07.002

Shore ND. Current and future management of locally advanced and metastatic prostate cancer. *Rev Urol*. 2020;22(3):110-123.

Shore ND, Saad F, Cookson MS, et al. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. *N Engl J Med*. 2020;382(23):2187-2196. doi:10.1056/NEJMoa2004325

Tweet 10

Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. *Eur Urol*. 2015;68(3):386-96. doi:10.1016/j.eururo.2014.11.039

Hu JR, Duncan MS, Morgans AK, et al. Cardiovascular effects of androgen deprivation therapy in prostate cancer: contemporary meta-analyses. *Arterioscler Thromb Vasc Biol*. 2020;40(3):e55-e64. doi:10.1161/ATVBAHA.119.313046

Meng F, Zhu S, Zhao J, et al. Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review. *BMC Cancer*. 2016;16(1):180. doi:10.1186/s12885-016-2221-5

Zhao J, Zhu S, Sun L, et al. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. *PLoS One*. 2014;9(9):e107516. doi:10.1371/journal.pone.0107516

Tweet 11

Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. *Eur Urol*. 2015;68(3):386-96. doi:10.1016/j.eururo.2014.11.039

Hu JR, Duncan MS, Morgans AK, et al. Cardiovascular effects of androgen deprivation therapy in prostate cancer: contemporary meta-analyses. *Arterioscler Thromb Vasc Biol*. 2020;40(3):e55-e64. doi:10.1161/ATVBAHA.119.313046

Meng F, Zhu S, Zhao J, et al. Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review. *BMC Cancer*. 2016;16(1):180. doi:10.1186/s12885-016-2221-5

Shore ND. Current and future management of locally advanced and metastatic prostate cancer. *Rev Urol*. 2020;22(3):110-123.

Sountoulides P, Rountos T. Adverse effects of androgen deprivation therapy for prostate cancer: prevention and management. *ISRN Urol*. 2013;2013:240108. doi:10.1155/2013/240108

Zhao J, Zhu S, Sun L, et al. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. *PLoS One*. 2014;9(9):e107516. doi:10.1371/journal.pone.0107516

Tweet 12

Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. *BJU Int*. 2008;102(11):1531-8. doi:10.1111/j.1464-410X.2008.08183.x

Sari Motlagh R, Abufaraj M, Mori K, et al. The Efficacy and safety of relugolix compared with degarelix in advanced prostate cancer patients: a network meta-analysis of randomized trials. *Eur Urol Oncol*. 2021. doi:10.1016/j.euo.2021.07.002

Shore ND, Saad F, Cookson MS, et al. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. *N Engl J Med*. 2020;382(23):2187-2196. doi:10.1056/NEJMoa2004325

Tweet 13

Dowling M, Hunter A, Biesty L, et al. Driving and disabling factors of noncurative oral chemotherapy adherence: a qualitative evidence synthesis. article. *Oncol Nurs Forum*. 2019;46(1):16-28. doi:10.1188/19.ONF.16-28

Lopes RD, Higano CS, Slovin SF, et al. Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. *Circulation*. 2021;144(16):1295-1307. doi:10.1161/CIRCULATIONAHA.121.056810

Melloni C, Slovin SF, Blemings A, et al. Cardiovascular safety of degarelix versus leuprolide for advanced prostate cancer: the PRONOUNCE trial study design. *JACC CardioOncol*. 2020;2(1):70-81. doi:10.1016/j.jaccao.2020.01.004

Tweet 15

Dowling M, Hunter A, Biesty L, et al. Driving and disabling factors of noncurative oral chemotherapy adherence: a qualitative evidence synthesis. article. *Oncol Nurs Forum*. 2019;46(1):16-28. doi:10.1188/19.ONF.16-28

Glossary

ADT, androgen deprivation therapy
AE, adverse events
ALT, alanine transaminase
ASCVD, atherosclerotic cardiovascular disease
AST, aspartate transaminase
BMI, body mass index
CI, confidence interval
CV, cardiovascular
CVD, cardiovascular disease
FSH, follicle-stimulating hormone
GnRH, gonadotropin-releasing hormone
HCP, health care provider
HDL, high-density lipoprotein
HR, hazard ratio
LH, luteinizing hormone
MACE, major adverse cardiovascular event
NA, not applicable
NCCN, National Comprehensive Cancer Network
PCa, prostate cancer
RR, relative risk
SOC, standard of care
Testo, testosterone
UTI, urinary tract infection
w/, with